Orum Therapeutics

Ascend to New Heights

Orum Therapeutics was founded in 2016, is headquartered in Daejeon, Korea & Lexington, MA, USA, United States, lists 51–200 employees, and has $268.0M in recorded funding across 4 rounds.

Employees
51–200
Founded
2016
Business Model
B2B
Website
orumrx.com
Total Funding
$268.0M
Last Round
$100.0M Venture RoundDec 2025
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 8 investors for this company. The full record is or through the API.

About

Orum Therapeutics is a public, clinical-stage biotechnology company developing degrader-antibody conjugates (DACs) through its proprietary TPD² platform, which combines catalytic targeted protein degradation with the tumor-targeting precision of therapeutic antibodies. Founded in 2016, the company is headquartered in Daejeon, South Korea, with a U.S. site in Lexington, Massachusetts. Its lead candidate, ORM-1153, is a CD123-targeting degrader-antibody conjugate in development for acute myeloid leukemia. In December 2025 Orum raised approximately $100 million (145 billion KRW) led by KB Investment, with participation from IMM Investment, Woori Venture Partners, Weiss Asset Management, and Korea Investment Partners.

Summary

Orum Therapeutics is a Biotech company based in Daejeon, Korea & Lexington, MA, USA, United States, founded in 2016. It lists 51–200 employees. It has raised $268.0M in total across 4 rounds, most recently a $100.0M Venture Round in Dec 2025. Investors include KB Investment, IMM Investment and KIP Global Pharma Private Equity Fund.

Funding History

Venture RoundVenture RoundDec 2025
$100.0M

Sign up to see all 4 events

Funding: Series B through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Orum Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/orum-therapeutics"><img src="https://indexed.vc/api/badge/company/orum-therapeutics" alt="Orum Therapeutics on Indexed.vc" width="260" height="76" /></a>